
Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

German company aims for the first EU approval for cell-cultured meat
The Cultivated B (Heidelberg, Germany) is the first company in the world to pre-register a partially cell-based meat product with the European Food...

Mithra raises €20m through private placement
Under the terms of the Private Placement, Armistice Capital committed to subscribe for 10 million new shares atz a share price of 2€ per share , of...

Donaldson Acquires Belgian Univercells Technologies for €138m
Headquartered in Nivelles, Belgium, Univercells Technologies employs over 100 people worldwide. The company has been acquired for a cash...

Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

NK cell therapy company NK:IO raises seed money
London-based UK New Cancer Therapeutics award winner (£1.6m) NK:IO Ltd has raised £1.2M bringing total equity financing to £3.2m. This,...